{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:01:42Z","timestamp":1793289702408,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018703","name":"European Innovation Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018703","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006678","name":"French Association of Liver Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006678","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-23-RHUS-0014"],"award-info":[{"award-number":["ANR-23-RHUS-0014"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-21-RHUS-0001"],"award-info":[{"award-number":["ANR-21-RHUS-0001"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","award":["2023 CSS13 HBV-LIRAGE ECTZ232901"],"award-info":[{"award-number":["2023 CSS13 HBV-LIRAGE ECTZ232901"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","award":["INCa-DGOS-Inserm-12561"],"award-info":[{"award-number":["INCa-DGOS-Inserm-12561"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jhep.2026.03.019","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T07:34:14Z","timestamp":1773992054000},"page":"289-300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French genomic medicine initiative"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3842-782X","authenticated-orcid":false,"given":"Claudia","family":"Campani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Laurent-Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9327-4590","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Villeret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmina","family":"Benmerabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Netter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7548-3703","authenticated-orcid":false,"given":"Yasmina","family":"Chouik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonore","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Merle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Bousquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5117-4842","authenticated-orcid":false,"given":"Marianne","family":"Ziol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Asif-Laidin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Seror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Ganne-Carrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Nahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal Ait","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Marisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Lequoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Bouattour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-1704","authenticated-orcid":false,"given":"Camille","family":"Tlemsani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0803-8551","authenticated-orcid":false,"given":"Massih","family":"Ningarhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Allaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5687-0334","authenticated-orcid":false,"given":"Jessica","family":"Zucman-Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-9353","authenticated-orcid":false,"given":"Jean-Charles","family":"Nault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.jhep.2026.03.019_bib1","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.019_bib2","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.019_bib3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.jhep.2026.03.019_bib4","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid [Internet]"},{"issue":"10391","key":"10.1016\/j.jhep.2026.03.019_bib5","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"The Lancet"},{"issue":"11","key":"10.1016\/j.jhep.2026.03.019_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2021.104313","article-title":"Rare variants of primary liver cancer: fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas","volume":"64","author":"Wege","year":"2021","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.jhep.2026.03.019_bib7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/annonc\/mdz383","article-title":"Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer","volume":"30","author":"Amatu","year":"2019","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.jhep.2026.03.019_bib8","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple Nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"issue":"6349","key":"10.1016\/j.jhep.2026.03.019_bib9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.jhep.2026.03.019_bib10","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","article-title":"Cholangiocarcinoma \u2014 novel biological insights and therapeutic strategies","volume":"20","author":"Ilyas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2026.03.019_bib11","article-title":"PFMG2025\u2013integrating genomic medicine into the national healthcare system in France","volume":"50","author":"Abadie","year":"2025","journal-title":"The Lancet Reg Health - Europe"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.019_bib12","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.jhep.2023.08.017","article-title":"Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab\/bevacizumab","volume":"79","author":"Limousin","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.019_bib13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"10272","key":"10.1016\/j.jhep.2026.03.019_bib14","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.019_bib15","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.019_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2 -rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.019_bib17","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.019_bib18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41591-023-02682-0","article-title":"Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme","volume":"30","author":"Sosinsky","year":"2024","journal-title":"Nat Med"},{"issue":"7793","key":"10.1016\/j.jhep.2026.03.019_bib19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.019_bib20","article-title":"Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis","volume":"8","author":"Letouz\u00e9","year":"2017","journal-title":"Nat Commun [Internet]"},{"issue":"412","key":"10.1016\/j.jhep.2026.03.019_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan6446","article-title":"Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia","volume":"9","author":"Ng","year":"2017","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.jhep.2026.03.019_bib22","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/GO.20.00425","article-title":"Hepatocellular carcinoma in Sub-Saharan Africa","author":"Kedar Mukthinuthalapati","year":"2021","journal-title":"JCO Glob Oncol"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.019_bib23","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-throughput genomics and clinical outcome in Hard-to-treat advanced cancers: results of the MOSCATO 01 trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.019_bib24","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/annonc\/mdz080","article-title":"Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial","volume":"30","author":"Tr\u00e9dan","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.019_bib25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/1078-0432.CCR-24-0036","article-title":"Phase II study of palbociclib in patients with tumors with CDK4 or CDK6 amplification: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) Subprotocol Z1C","volume":"31","author":"O\u2019Hara","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.019_bib26","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1038\/s41467-020-19288-6","article-title":"Immune modulatory effects of oncogenic KRAS in cancer","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.019_bib27","article-title":"New insights into the pathophysiology and clinical care of rare primary liver cancers","volume":"3","author":"Gigante","year":"2021","journal-title":"JHEP Rep"},{"issue":"7","key":"10.1016\/j.jhep.2026.03.019_bib28","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1038\/s41591-025-03715-6","article-title":"Feasibility of multiomics tumor profiling for guiding treatment of melanoma","volume":"31","author":"Miglino","year":"2025","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.jhep.2026.03.019_bib29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.019_bib30","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826001455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826001455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:44:44Z","timestamp":1784133884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826001455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0168827826001455"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.03.019","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French genomic medicine initiative","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}